MONTREAL, April 3, 2017 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for chronic hepatitis B and D infection, today announced that the European Association for the Study of the Liver (EASL) selection committee has accepted five Replicor abstracts for presentation at the EASL 2017 annual meeting to be held April 19-23, 2017 in Amsterdam, The Netherlands.
Four poster presentations will disclose new clinical and mechanistic data on the activity of NAPs against chronic hepatitis B infection:
A fifth late breaking poster presentation will include 1 year post-treatment follow-up and new analysis of HBV RNA and HBcrAg dynamics during NAP-based combination therapy in patients with chronic hepatitis B / hepatitis D co-infection:
Replicor’s presentations will be available on the company’s website at the end of the conference at www.replicor.com/science/conference-presentations. For the 2017 EASL Meeting: https://ilc-congress.eu/.
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV infection. For further information about Replicor please visit our website at www.replicor.com